Substudy C of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A phase II study of darolutamide (DARO) selected by androgen-receptor (AR) circulating tumor DNA (ctDNA) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) after prior AR pathway inhibitors (ARPIs). Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Ong, Michael
  • Chi, Kim N
  • Hotte, Sebastien J
  • Winquist, Eric
  • Saad, Fred
  • Ferrario, Cristiano
  • Macfarlane, Robyn Jane
  • Kolinsky, Michael Paul
  • Hansen, Aaron Richard
  • Salim, Muhammad
  • Kollmannsberger, Christian K
  • Lalani, Aly-Khan
  • Seymour, Lesley K
  • Mukherjee, Som D
  • Kwan, Edmond Michael
  • Sherry, Max
  • Tu, Dongsheng
  • Jafri, Mariam
  • Wyatt, Alexander William
  • Tu, Wei

publication date

  • June 2025